Kainos Progresses Parkinson’s Drug US Trials Amid Deal Prospects
US Phase II Study Of FAF1 Inhibitor Begins
Executive Summary
Following ABL Bio’s sizable Parkinson’s disease drug deal with Sanofi early this year, Korean bioventure Kainos Medicine is under the spotlight as its novel PD drug candidate enters Phase II in the US.
You may also be interested in...
Novartis Will Co-Develop UCB’s Alpha-Syn Inhibitor For Parkinson’s
Deal Snapshot: Seeking to bring a disease-modifying Parkinson’s drug to market, Novartis will team with UCB on developing and commercializing UCB0599, a Phase II oral alpha-synuclein inhibitor.
Asia Deal Watch: Junshi, Rxilient Form Joint Venture Around Toripalimab
Plus deals involving Biorchestra, Takeda/F-star, TaiGen/Joincare, Dr Reddy’s/Eris, Kaken/bitBiome, CJ Bioscience/4D Pharma, Ono/Macomics, Daiichi Sankyo/Zymeworks, Celltrion/Genuv and more.
Celltrion Eyes M&A, Global Expansion And Novel Drugs As Founder Returns
Celltrion founder and chairman Jung Jin Seo has outlined why he has decided to return to the Korean biosimilars major and the business priorities for the group if it is to emerge as a top-tier global biopharma operation.